Ampio To Test Inhaled COVID-19 Treatment In India
The Drugs Controller General of India (DCGI) of the Central Drugs Standard Control Organization (CDSCO) has approved Phase 2…
Ampio Pharma Reports Received Approval From Drugs Controller General Of India To Begin AP-019 Phase 2 Study In India
Ampio Pharmaceuticals (NYSE:AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced regulatory approval from the Drugs
Why Ampio Pharmaceuticals Stock Is Trading Higher Today
Ampio Pharmaceuticals Inc (AMEX:AMPE) shares are trading higher Wednesday after the company announced top-line results from the AP-013 Phase III study of Ampion in patients suffering from severe osteoarthritis of the knee (OAK).
EXCLUSIVE: Ampio’s Ampion Shows Benefit In Late-Stage Knee Osteoarthritis Study
Ampio Pharmaceuticals Inc (NYSE: AMPE) has reported top-line results from the AP-013 Phase 3 trial evaluating the Company's intra-articular (IA) injection of Ampion in adults with pain due to severe osteoarthritis of the knee (OAK).
Ampio Pharmaceuticals Announces New Research Manuscript On Anti-Inflammatory Mode Of Action
Ampio Pharmaceuticals, Inc. (NYSE:AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions for which there are limited treatment options,
Ampio Pharmaceuticals Q2 EPS $(0.02), Inline
Ampio Pharmaceuticals (AMEX:AMPE) reported quarterly losses of $(0.02) per share which met the analyst consensus estimate. This is unchanged from the same period last year.
Earnings Scheduled For August 4, 2021
Companies Reporting Before The Bell
• UroGen Pharma (NASDAQ:URGN) is projected to report earnings for its second quarter.
Ampio’s Phase 2 Study Of Inhaled Ampion In COVID-19 Patients Gets Underway
Ampio Pharmaceuticals, Inc. (NYSE: AMPE) announced an update to its COVID-19 program that is evaluating its lead asset Ampion.
The Daily Biotech Pulse: AstraZeneca, Biogen Face Clinical Trial Disappointments, Novavax Studies Coronavirus-Flu Combo Vaccine, Decision Day For Takeda
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 14)
Ampio Stock Jumps On Enrollment Expansion Of Mid-Stage COVID-19 Trial To India With Inhaled Ampion
Ampio Pharmaceuticals Inc (NYSE:AMPE) has received regulatory approval to expand enrollment of its AP-019 Phase 2 study to India, assessing inhaled…